Synthesis and biological activities of NB-506 analogues modified at the glucose group.

Abstract A new indolocarbazole compound, NB-506 ( 1 ), modified at the glucose group yielded a β- d -glucopyranoside, J-107,088 ( 2 ), which showed potent anticancer activity. A β- d -ribofuranoside, J-109,534 ( 3 ), was found to be 6 times more potent than J-107,088 at inhibiting topoisomerase I.